Person:
Hernández Sánchez, María

Profile Picture
First Name
María
Last Name
Hernández Sánchez
URI
https://hdl.handle.net/20.500.14352/86320
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Farmacia
Department
Bioquímica y Biología Molecular
Area
Bioquímica y Biología Molecular
Identifiers
UCM identifierORCIDScopus Author IDWeb of Science ResearcherIDDialnet ID

Filters

2020 - 20236
Reset filters

Settings

End date: 2023 × Start date: 2020 ×

Search Results

Now showing 1 - 6 of 6
  • Thumbnail Image
    Item
    From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct
    (Cancers, 2021) González Gascón y Marín, Isabel; Muñoz Novas, Carolina; Rodríguez Vicente, Ana-Eugenia; Quijada Álamo, Miguel; Hernández Sánchez, María; Pérez Carretero, Claudia; Ramos Ascanio, Victoria; Hernández Rivas, José Ángel
    hronic lymphocytic leukemia (CLL) is an extremely heterogeneous disease. With the advent of oral targeted agents (Tas) the treatment of CLL has undergone a revolution, which has been accompanied by an improvement in patient’s survival and quality of life. This paradigm shift also affects the value of prognostic and predictive biomarkers and prognostic models, most of them inherited from the chemoimmunotherapy era but with a different behavior with Tas. This review discusses: (i) the role of the most relevant prognostic and predictive biomarkers in the setting of Tas; and (ii) the validity of classic and new scoring systems in the context of Tas. In addition, a critical point of view about predictive biomarkers with special emphasis on 11q deletion, novel resistance mutations, TP53 abnormalities, IGHV mutational status, complex karyotype and NOTCH1 mutations is stated. We also go over prognostic models in early stage CLL such as IPS-E. Finally, we provide an overview of the applicability of the CLL-IPI for patients treated with Tas, as well as the emergence of new models, generated with data from patients treated with Tas.
  • Thumbnail Image
    Item
    Cine en compañía para prevenir enfermedades
    (2023) Valderrama Conde, María José; Linares Gómez, María; Ayllón Santiago, Tania; De Francisco Martínez, Patricia; Bravo Vázquez, Daniel Antonio; López Ejeda, Noemí; Marrodán Serrano, María Dolores; Juan Chocano, María Del Carmen De; García Redondo, Alberto; Hernández Sánchez, María; López Vázquez de la Torre, Mª de la O ; Alonso Monge, Rebeca María Del Mar; Díez Orejas, Rosalía María; Navarro González De Mesa, Elisa; Ancos Pintado, Raquel ; Campo Moreno, Rosa del ; Rodríguez García, Alba ; García Vicente, Roberto ; Álvarez Sánchez-Redondo, Noemí ; Hernando Ospina, Natalia ; Rodríguez Solana, Patricia ; Pulido Vadillo, Mario ; León Rodríguez, Sergio ; Álvaro Llorente, Laura ; Pedrero Tomé, Roberto ; Alaminos Torres, Ana
    El proyecto atiende la necesidad social de colectivos desfavorecidos o en riesgo de exclusión (sin hogar, presidiarios, discapacitados o enfermos mentales, mujeres) de ayuda al conocimiento sobre determinadas enfermedades que les afectan con una incidencia más alta que al resto de población (infecciosas, metabólicas, mentales, derivadas de consumo de drogas o alcohol o malnutrición). Adicionalmente, acusan carencias de compañía, entretenimiento o posibilidad de socialización, derivadas de sus circunstancias vitales. Los estudiantes que cursan titulaciones del ámbito de ciencias y ciencias de la salud profundizan en el aprendizaje de estas enfermedades realizando un servicio a estas personas de acompañamiento e información sobre prevención y/o tratamiento de las mismas. Trabajan en equipos multidisciplinares (distintas titulaciones y cursos) y desarrollan competencias profesionales en salud pública, así como transversales, como colaboración y coordinación en equipo, análisis crítico, expresión oral o diseño de materiales. Las actividades de servicio se llevan a cabo mediante visitas a los centros sociales asociados, donde se acompaña a los colectivos con proyección de películas sobre las enfermedades de interés, realización de juegos y coloquio. El proyecto comenzó en el curso 2017-18 (dentro de la convocatoria INNOVA) y ha ampliado el ámbito de conocimiento (bioquímica, biología molecular, epidemiología, microbiología, nutrición), facultades/organismos (Facultades de Biología, Farmacia, Medicina, Químicas, Hospitales 12 de Octubre y Ramón y Cajal), departamentos (Bioquímica y Biología molecular, Genética, Fisiología y Microbiología, Microbiología y Parasitología, Biodiversidad, Ecología y Evolución), asignaturas / titulaciones de los estudiantes, tipo de enfermedades abordadas y grupos y centros sociales atendido (distintas entidades y Ayuntamiento de Madrid).
  • Thumbnail Image
    Item
    Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications
    (International Journal of Cancer, 2020) Pérez‐Carretero, Claudia; Hernández Sánchez, María; González, Teresa; Quijada‐Álamo, Miguel; Martín‐Izquierdo, Marta; Vidal, María‐Jesús; García de Coca, Alfonso; Hernández Rivas, José Ángel; Aguilar, Carlos; Vargas‐Pabón, Manuel; Alonso, Sara; Sierra, Magdalena; Rubio‐Martínez, Araceli; Dávila, Julio; Díaz‐Valdés, José R.; Queizán, José‐Antonio; Benito, Rocío; Rodríguez‐Vicente, Ana E.; Hernández‐Rivas, Jesús‐María
    Chromosome 14q32 rearrangements/translocations involving the immunoglobulinheavy chain (IGH) are rarely detected in chronic lymphocytic leukemia (CLL). Theprognostic significance of the IGH translocation is controversial and its mutational profile remains unknown. Here, we present for the first time a comprehensive next-generation sequencing (NGS) analysis of 46 CLL patients with IGH rearrangement(IGHR-CLLs) and we demonstrate that IGHR-CLLs have a distinct mutational profilewith recurrent mutations in BRAF and HIST1H1E genes. Interestingly, BCL2 and FBXW7mutations were significantly associated with this subgroup and almost half of BCL2, IGLL5 and HISTH1E mutations reported were previously identified in non-Hodgkin lymphomas. Notably, IGH/BCL2 rearrangements were associated with a lower mutation frequency and carried BCL2 and IGLL5 mutations, while the other IGHR-CLLs had mutations in genesrelated to poor prognosis (NOTCH1, SF3B1 and TP53) and shorter time to first treat-ment (TFT). Moreover, IGHR-CLLs patients showed a shorter TFT than CLL patients carrying 13q−, normal fluorescence in situ hybridization (FISH) and +12 CLL, NOTCH1, SF3B1, TP53, BIRC3 and BRAF werealso mutated. The presence of these mutations not only was an independent risk fac-tor within IGHR-CLLs, but also refined the prognosis of low-risk cytogenetic patients(13q−/normal FISH). Hence, our study demonstrates that IGHR-CLLs have a distinct mutational profile from the majority of CLLs and highlights the relevance of incorporating NGS and the status ofIGHby FISH analysis to refine the risk-stratification CLL model.
  • Thumbnail Image
    Item
    CRISPR/Cas9 in Chronic Lymphocytic Leukemia
    (Encyclopedia, 2022) Hernández Sánchez, María
    Genome-editing systems such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology have uncovered new opportunities to model diseases such as chronic lymphocytic leukemia. CRISPR/Cas9 is an important means of advancing functional studies of Chronic Lymphocytic Leukemia (CLL) through the incorporation, elimination and modification of somatic mutations in CLL models.
  • Thumbnail Image
    Item
    Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models
    (2023) Hacken, Elisa ten; Yin, Shanye; Redd, Robert; Hernández Sánchez, María; Clement, Kendell; Brunsting Hoffmann, Gabriela; Regis,Fara F.; Witten, Elizabeth; Li, Shuqiang; Neuberg, Donna; Pinello, Luca; Livak, Kenneth J.; Wu, Catherine J.
  • Thumbnail Image
    Item
    High-Throughput CRISPR Screening in Hematological Neoplasms
    (Cancers, 2022) Ancos-Pintado, Raquel; Bragado-García, Irene; Morales, María Luz; García-Vicente, Roberto; Arroyo-Barea, Andrés; Rodríguez-García, Alba; Martínez López, Joaquín; Linares Gómez, María; Hernández Sánchez, María
    CRISPR is becoming an indispensable tool in biological research, revolutionizing diverse fields of medical research and biotechnology. In the last few years, several CRISPR-based genome-targeting tools have been translated for the study of hematological neoplasms. However, there is a lack of reviews focused on the wide uses of this technology in hematology. Therefore, in this review, we summarize the main CRISPR-based approaches of high throughput screenings applied to this field. Here we explain several libraries and algorithms for analysis of CRISPR screens used in hematology, accompanied by the most relevant databases. Moreover, we focus on (1) the identification of novel modulator genes of drug resistance and efficacy, which could anticipate relapses in patients and (2) new therapeutic targets and synthetic lethal interactions. We also discuss the approaches to uncover novel biomarkers of malignant transformations and immune evasion mechanisms. We explain the current literature in the most common lymphoid and myeloid neoplasms using this tool. Then, we conclude with future directions, highlighting the importance of further gene candidate validation and the integration and harmonization of the data from CRISPR screening approaches.